FDA CLINICAL HOLD ON ANTINEOPLASTONS LIFTED!

Burzynski Research Institute, Inc. Announces Lifting of the FDA Partial Clinical Hold – Phase 3 Clinical Study Agreed Upon  HOUSTON, June 23, 2014 – (PR Newswire) – The Burzynski Research Institute, Inc.  (BRI) announced today that U.S. Food and Drug...

New Personalized Therapy Website

Check out the patients testimonials on our sister website www.burzynskiapt.org. Dr. Burzynski has had phenomenal success in treating cancer with Personalized Gene Targeted Therapy.  Patients may travel to Houston and receive therapy without restrictions. read...

High Grade Glioma Peer Review Article

Another Peer-review ANP publication was released this week! The Journal of Cancer Therapy (Scientific Research Publisher) is presenting “A Phase II Study of Antineoplastons A10 and AS2-1 in Children with High Grade Glioma. Final Report (Protocol BT-06), and Review of...